BioVersys Successfully Completes IPO at CHF 36 per Share

BioVersys AG has completed its Initial Public Offering (IPO), pricing its shares at CHF 36.00 each, leading to a market capitalization of CHF 213 million. The company has placed 2,222,221 shares in the offering, which includes an over-allotment option of 138,888 shares. The shares commence trading on the SIX Swiss Exchange on February 07, 2025, under the ticker “BIOV”.

The IPO is expected to provide BioVersys with gross proceeds of approximately CHF 80 million. The funds are intended primarily for the development of BV100 and alpibectir, its leading therapeutic candidates aimed at combating multi-drug resistant bacteria. The company, in conjunction with GSK and others, will use these proceeds to advance its clinical trials and pipeline development.

BioVersys' inclusion in the Swiss Performance Index (SPI) is anticipated by February 10, 2025, marking a significant step in its ongoing growth strategy. The IPO was coordinated by Citi, UBS, and Stifel, among others.